The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry-Reference-Cited by-同舟云学术

The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry

Published:2021-11 Issue: Volume:158 Page:217-224
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Ruste Valentine^ORCID,Goldschmidt Vincent^ORCID,Laparra Ariane,Messayke Sabine^ORCID,Danlos Francois-Xavier,Romano-Martin Patricia,Champiat Stéphane,Voisin Anne-Laure^ORCID,Baldini Capucine,Massard Christophe,Laghouati Salim,Marabelle Aurélien,Lambotte Olivier,Michot Jean-Marie

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical practice guideline;Brahmer;J Clin Oncol,2018

2. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†;Haanen;Ann Oncol,2017

3. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer;Reck;N Engl J Med,2016

4. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance;Martins;Nat Rev Clin Oncol,2019

5. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial;Hodi;Lancet Oncol,2018

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncology-respirology: a discipline in dire need;Trends in Cancer;2024-09

3. Uncommon Adverse Events of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Case Reports;Cancers;2024-05-16

4. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation;Archives of Pathology & Laboratory Medicine;2024-04-16

5. Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management;Frontiers in Immunology;2024-03-22